drugset / Trial / NCT02072434

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

NCT02072434

Phase 3 Completed 2199 enrolled Daiichi Sankyo
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin. People with atrial fibrillation (irregular heartbeat) might be able to join. Their doctors must plan to use shock to make their hearts beat normally. About 2200 people from different countries will join. They will have an equal chance of receiving either treatment. They are anticipated to be in the study for around 82 days. Tests will include physicals and finger-pricks. Participants will provide blood and urine samples.

Timeline

Start
2014-03-25
Primary completion
2016-02-03
Completion
2016-02-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule 30 mg Oral
Subject Edoxaban Small molecule 60 mg Oral
Comparator Enoxaparin sodium Other / unclassified
Comparator Warfarin Small molecule 1 mg Oral
Comparator Warfarin Small molecule 2.5 mg Oral

Indications